{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:43:17Z","timestamp":1792478597783,"version":"4.5.0"},"reference-count":40,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15864","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:41:16Z","timestamp":1789468876000},"page":"1-10","source":"Crossref","is-referenced-by-count":0,"title":["Optimal timing of stereotactic radiosurgery with first\u2011line osimertinib in EGFR\u2011mutant non\u2011small cell lung cancer brain metastases: Immediate, early\u2011consolidation and salvage strategies"],"prefix":"10.3892","volume":"32","author":[{"given":"Xiaona","family":"Zhuang","sequence":"first","affiliation":[{"name":"Department of Abdominopelvic Medical Oncology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine\u2011Hebei, Cangzhou, Hebei 061000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Abdominopelvic Medical Oncology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine\u2011Hebei, Cangzhou, Hebei 061000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Abdominopelvic Medical Oncology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine\u2011Hebei, Cangzhou, Hebei 061000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangying","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Abdominopelvic Medical Oncology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine\u2011Hebei, Cangzhou, Hebei 061000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangkun","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Abdominopelvic Medical Oncology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine\u2011Hebei, Cangzhou, Hebei 061000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"key20261020093225_b1-ol-32-5-15864","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"key20261020093225_b2-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1016\/j.cllc.2018.01.007","article-title":"Non-small-cell lung cancer with brain metastasis at presentation","volume":"19","author":"Waqar","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"key20261020093225_b3-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"1973241","DOI":"10.1155\/2020\/1973241","article-title":"EGFR Polymorphism and survival of NSCLC patients treated with TKIs: A systematic review and meta-analysis","volume":"2020","author":"Jurisic","year":"2020","journal-title":"J Oncol"},{"key":"key20261020093225_b4-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s11033-025-10447-w","article-title":"Investigating the frequencies of EGFR mutations and EGFR single nucleotide polymorphisms genotypes and their predictive role in NSCLC patients in Republic of Serbia","volume":"52","author":"Obradovi\u0107","year":"2025","journal-title":"Mol Biol Rep"},{"key":"key20261020093225_b5-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20261020093225_b6-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): A randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"key":"key20261020093225_b7-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3892\/ol.2022.13649","article-title":"Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: A systematic review and meta-analysis","volume":"25","author":"Obradovic","year":"2022","journal-title":"Oncol Lett"},{"key":"key20261020093225_b8-ol-32-5-15864","first-page":"381","article-title":"Brain and other central nervous system tumor statistics, 2021","volume":"71","author":"Miller","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key20261020093225_b9-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","article-title":"Current approaches to the management of brain metastases","volume":"17","author":"Suh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"key20261020093225_b10-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12931-021-01741-9","article-title":"Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation","volume":"22","author":"Li","year":"2021","journal-title":"Respir Res"},{"key":"key20261020093225_b11-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ijc.32097","article-title":"Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis","volume":"145","author":"Yi","year":"2019","journal-title":"Int J Cancer"},{"key":"key20261020093225_b12-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ijrobp.2017.04.006","article-title":"Single-fraction stereotactic radiosurgery (SRS) alone versus surgical resection and SRS for large brain metastases: A multi-institutional analysis","volume":"99","author":"Prabhu","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20261020093225_b13-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.lungcan.2018.03.013","article-title":"Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients","volume":"119","author":"Yomo","year":"2018","journal-title":"Lung Cancer"},{"key":"key20261020093225_b14-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11060-023-04442-z","article-title":"EGFR-mutated non-small lung cancer brain metastases and radiosurgery outcomes with a focus on leptomeningeal disease","volume":"164","author":"Alzate","year":"2023","journal-title":"J Neurooncol"},{"key":"key20261020093225_b15-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11060-022-04145-x","article-title":"Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer","volume":"160","author":"Hui","year":"2022","journal-title":"J Neurooncol"},{"key":"key20261020093225_b16-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3390\/ijms22020593","article-title":"Treatment of brain metastases of non-small cell lung carcinoma","volume":"22","author":"Rybarczyk-Kasiuchnicz","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20261020093225_b17-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13014-021-01955-7","article-title":"Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: A retrospective study","volume":"16","author":"Zhai","year":"2021","journal-title":"Radiat Oncol"},{"key":"key20261020093225_b18-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13014-024-02578-4","article-title":"Effects of EGFR-TKIs combined with intracranial radiotherapy in EGFR-mutant non-small cell lung cancer patients with brain metastases: A retrospective multi-institutional analysis","volume":"20","author":"He","year":"2025","journal-title":"Radiat Oncol"},{"key":"key20261020093225_b19-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ijrobp.2019.02.051","article-title":"Optimal sequence of local and EGFR-TKI therapy for EGFR-mutant non-small cell lung cancer with brain metastases stratified by number of brain metastases","volume":"104","author":"Miyawaki","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20261020093225_b20-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1186\/s12885-023-11548-0","article-title":"First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell lung cancer with brain metastases: A systematic review and meta-analysis","volume":"23","author":"Song","year":"2023","journal-title":"BMC Cancer"},{"key":"key20261020093225_b21-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1007\/s11033-021-06379-w","article-title":"Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: A systematic review","volume":"48","author":"Obradovic","year":"2021","journal-title":"Mol Biol Rep"},{"key":"key20261020093225_b22-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: Proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20261020093225_b23-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","article-title":"Radiation therapy for brain metastases: An ASTRO clinical practice guideline","volume":"12","author":"Gondi","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"key20261020093225_b24-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20261020093225_b25-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"key20261020093225_b26-ol-32-5-15864","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","author":"United States Department of Health and Human Services","year":"2017"},{"key":"key20261020093225_b27-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1200\/JCO.2016.69.7144","article-title":"Management of brain metastases in tyrosine kinase inhibitor-na\u00efve epidermal growth factor receptor-mutant non-small-cell lung cancer: A retrospective multi-institutional analysis","volume":"35","author":"Magnuson","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20261020093225_b28-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.lungcan.2018.05.014","article-title":"Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis","volume":"122","author":"Wang","year":"2018","journal-title":"Lung Cancer"},{"key":"key20261020093225_b29-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ijrobp.2021.05.125","article-title":"Clinical value of upfront cranial radiation therapy in osimertinib-treated epidermal growth factor receptor-mutant non-small cell lung cancer with brain metastases","volume":"111","author":"Yu","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20261020093225_b30-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/ijc.33904","article-title":"Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis","volume":"150","author":"Zhao","year":"2022","journal-title":"Int J Cancer"},{"key":"key20261020093225_b31-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1200\/JCO.23.02668","article-title":"Tyrosine kinase inhibitors with and without up-front stereotactic radiosurgery for brain metastases From EGFR and ALK oncogene-driven non-small cell lung cancer (TURBO-NSCLC)","volume":"42","author":"Pike","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20261020093225_b32-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijrobp.2019.12.042","article-title":"Pattern of recurrence analysis in metastatic EGFR-Mutant NSCLC treated with osimertinib: Implications for consolidative stereotactic body radiation therapy","volume":"107","author":"Guo","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20261020093225_b33-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20261020093225_b34-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","article-title":"Radiation-induced tumor immune microenvironments and potential targets for combination therapy","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"key20261020093225_b35-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s11060-023-04452-x","article-title":"Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: A large retrospective cohort study and meta-analyses","volume":"164","author":"Kuan","year":"2023","journal-title":"J Neurooncol"},{"key":"key20261020093225_b36-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"1770066","DOI":"10.3389\/fonc.2026.1770066","article-title":"Early brain radiotherapy combined with third-generation EGFR-TKIs improves survival in EGFR-mutant NSCLC with synchronous brain metastases: A multi-center retrospective analysis","volume":"16","author":"Kong","year":"2026","journal-title":"Front Oncol"},{"key":"key20261020093225_b37-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13014-017-0840-x","article-title":"Stereotactic radiosurgery versus whole-brain radiotherapy after intracranial metastasis resection: A systematic review and meta-analysis","volume":"12","author":"Lamba","year":"2017","journal-title":"Radiat Oncol"},{"key":"key20261020093225_b38-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-025-01083-1","article-title":"Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care","volume":"22","author":"Mansouri","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"key20261020093225_b39-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"103549","DOI":"10.1016\/j.jtho.2026.01.001","article-title":"Osimertinib and stereotactic radiosurgery for brain metastases in EGFR-mutated lung cancer: The STARLET joint analysis of OUTRUN and LUOSICNS randomized trials","volume":"21","author":"Lee","year":"2026","journal-title":"J Thorac Oncol"},{"key":"key20261020093225_b40-ol-32-5-15864","doi-asserted-by":"publisher","first-page":"25067","DOI":"10.1038\/s41598-025-10042-w","article-title":"In the context of the era of targeted therapy: Evaluation of the survival benefits of different local treatment modalities for patients with 1\u20133 brain metastases from non-small cell lung cancer","volume":"15","author":"Sun","year":"2025","journal-title":"Sci Rep"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:32:32Z","timestamp":1792477952000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,15]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15864","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}